Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025Denifanstat received Breakthrough Therapy ...
Sagimet Biosciences Inc. has obtained IND clearance from the FDA for TVB-3567 (ASC-60), a selective small-molecule fatty acid ...
TVB-3567 is the Company's second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences ...
Sagimet Biosciences (SGMT) announced the clearance of its Investigational New Drug, IND, application for TVB-3567, the Company’s second fatty ...
TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 ...
A recent study reveals how the expansion and functional divergence of terpene synthase genes (TPSs) in flowering plants ...
Positive top-line data from phase II and III studies of lorundrostat for treating uncontrolled or resistant hypertension ...
Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of ...
Bifloranes, also known as serrulatanes, feature a distinct 6,6-bicyclic framework and a prenyl side chain, showcasing a wide range of biological activities such as anti-inflammatory, antimalarial, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback